New triple therapy targets Hard-to-Treat bile duct cancer
NCT ID NCT07159217
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 29 times
Summary
This study tests a combination of three drugs (disitamab vedotin, lenvatinib, and a PD-1 inhibitor) in 65 adults with advanced HER2-positive bile duct cancer that cannot be removed by surgery. The goal is to see if the combo shrinks tumors and controls the disease. Participants will be closely monitored for side effects and how long the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese Academy of Medical Sciences, Peking Union Medical College Hospital
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.